Skip to main content


Caribou is applying its next-generation CRISPR genome editing technology in the discovery and development of novel therapeutic candidates. Current areas of focus include genome-edited off-the-shelf allogeneic CAR-T cell and natural killer (NK) cell therapies for the treatment of patients with advanced malignancies.

Program CB-010, T cell, Target CD19, Editing CAR into TRAC PD-1 KO, Indications R/R B-NHL, Phase 1. Program CB-011, T cell, Target BCMA, Editing CAR into TRAC HLA-E-B2M-peptide into B2M, Indications R/R MM, Discovery Phase. Program CB-012, T cell, Target CD371, Editing Armoring, Indications R/R AML, Discovery Phase. Program CB-020, iNK cell, Editing Armoring, Indications Solid Tumors, Discovery Phase.

R/R B-NHL: relapsed/refractory B cell non-Hodgkin lymphoma
R/R MM: relapsed/refractory multiple myeloma
R/R AML: relapsed/refractory acute myeloid leukemia

Current clinical trial

For more information on Caribou Biosciences’ clinical trial, please visit